Federal Council adopts framework agreement on the reimbursement of innovative cancer therapies

11. November 2022 – At its meeting on 9 November 2022, the Federal Council approved the framework agreement on the reimbursement of autologous CAR-T cell therapies. Access to these therapies will thus be regulated more clearly and standardised.

For more information, see here.